Friday, 16 October 2026European Markets

LAVIDE HOLDING Stock Went Up By Over 10% So Far On Tuesday

Loading stream...

LAVIDE HOLDING, a Netherlands-based holding company formerly known as Qurius N.V, has seen a significant increase in share value despite numerous consecutive session losses. At 14:15 EST on Tuesday, shares unexpectedly surged 10.89% to EUR0.22. Contrastingly, the company's listing in the AEX-Index showed slight downward momentum, with losses totaling 0.94% to EUR759.02 since a previous upswing.

LAVIDE HOLDING's Performance

The company's previous closing price showed a decline of 53.33% year to date, falling to EUR0.24. LAVIDE HOLDING is generally regarded as a reliable entity, operating as an inactive holding corporation, but was once engaged in delivering comprehensive technology solutions. In a concerning trend, LAVIDE HOLDING recorded an earnings per share (EPS) loss for the trailing twelve months at -EUR0.04, indicating a loss through their stock during this period.

Trade Volume and Movement Averages

Trade volume, a key market activity indicator, is seeing a decrease with LAVIDE HOLDING's stock. The company reported a last trade volume of 3805 on Tuesday, a 44.56% decrease compared to its average trade volume of 6864. This decrease could signal lower trading interests among investors.

An examination of moving averages demonstrates a significant decline in LAVIDE HOLDING's value in relation to its 50-day and 200-day moving averages, both set at EUR0.28. This notably underscores the declining performance of Lavide Holding, emphasized by its current inactivity.

Stochastic Oscillator Indications

The stochastic oscillator, a tool to measure overbought and oversold stock conditions, presents LAVIDE HOLDING's stock as overbought. This indicates a potential need for cautious trading, as overbought conditions commonly precede price declines.

More news about LAVIDE HOLDING (LVIDE.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com